本論文已被瀏覽 42 次， [ ] 9 次，[ ] [ ]
Many new drugs fail to pass clinical trials every year because of poor bioavailability. More than 40% of those New Chemical Entities fail to reach commercialization due to poor solubility. Nanotechnology, which can increase the active surface area, often is employed to improve the solubility of drugs. However, existing technologies using top-down approaches such as grinding, milling, and homogenization have issues of inconsistent particle size distribution, batch contamination, scalability, and high maintenance costs. There is a need to develop a bottom-up nanotechnology approach. This thesis focuses on the development and commercialization of GenSyn’s particle engineering capabilities using in-house Controlled Flow Cavitation (CFC™) Technology for its use in pharmaceutical processing. Based on the initial results, the commercialization of GenSyn’s particle engineering capabilities is considered feasible.